[Federal Register: February 19, 2003 (Volume 68, Number 33)]
[Notices]               
[Page 8039]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr19fe03-109]                         


-----------------------------------------------------------------------


DEPARTMENT OF HEALTH AND HUMAN SERVICES


National Institutes of Health


 
National Institute on Drug Abuse; Notice of Closed Meeting


    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.


    Name of Committee: National Institute on Drug Abuse Speical 
Emphasis Panel, ``Pharmacovigilance Database for Anti-Addiction 
Medications'' (Topics 044).
    Date: March 5, 2003.
    Time: 1:30 p.m. to 3:30 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852, (Telephone Conference 
Call).
    Contact Person: Eric Zatman, Contract Review Specialist, Office 
of Extramural Affairs, National Institute on Drug Abuse, National 
Institutes of Health, DHHS, 6001 Executive Boulevard, Room 3158, MSC 
9547, Bethesda, MD 20892-9547, (301) 435-1438.


(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug 
Scientist Development Award for Clinicians, Scientist Development 
Awards, and Research Scientist Awards; 93.278, Drug Abuse National 
Research Service Awards for Research Training; 93.279, Drug Abuse 
Researh Programs, National Institutes of Health, HHS)


    Dated: February 10, 2003.
LaVerne Y. Stringfield,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 03-3912 Filed 2-18-03; 8:45 am]

BILLING CODE 4140-01-M